Description: Cizzle Biotechnology Holdings Plc engages in developing a blood test for the early detection of various forms of lung cancer. It develops CIZ1B protein gene and its potential as a diagnostic biomarker for detection and management of lung cancer. The company's Ciz1 promotes DNA replication and its organization and control. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings Plc was incorporated in 2004 and is headquartered in London, the United Kingdom.
Home Page: www.cizzlebiotechnology.com
CIZ Technical Analysis
60 Gracechurch Street
London,
EC3V 0HR
United Kingdom
Phone:
Officers
| Name | Title |
|---|---|
| Mr. Allan John Syms | Exec. Chairman |
| Prof. Dawn Coverley | Founder, Chief Scientific Officer & Non-Exec. Director |
| Mr. Nigel R. Lee | Fin. Director & Exec. Director |
| Mr. Morgan Williams | Head of Commercialisation for Yorkshire Cancer Research and Board Observer |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 1.525 |
| Price-to-Book MRQ: | 2.1774 |
| Price-to-Sales TTM: | 200.4826 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 4 |